Loading
HKSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
HK$16.33
−HK$0.18 · -1.09%
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.
Latest quote
HK$16.33
−HK$0.18 · -1.09%
Regular session · HKT · Market data may be delayed.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.
Day range
Current HK$16.33
52-week range
Current HK$16.33
Regular session · HKT · Market data may be delayed.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.
Day range
Current HK$16.33
52-week range
Current HK$16.33
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 40.42B CNY | 41.07B CNY | 41.4B CNY | 43.95B CNY | 39.01B CNY |
| Cost of goods sold | 20.26B CNY | 21.37B CNY | 21.72B CNY | 23.17B CNY | 20.23B CNY |
| Gross profit | 20.16B CNY | 19.7B CNY | 19.68B CNY | 20.78B CNY | 18.78B CNY |
| Research and development | 3.91B CNY | 3.64B CNY | 4.37B CNY | 4.3B CNY | 3.83B CNY |
| Selling, general, and administrative | 6.8B CNY | 6.47B CNY | 14.2B CNY | 10.16B CNY | 9.95B CNY |
| Operating expenses | 17.63B CNY | 15.46B CNY | 16.5B CNY | 17.15B CNY | 16.06B CNY |
| Interest income | 292.73M CNY | 404.64M CNY | 327.48M CNY | 282.63M CNY | 233.73M CNY |
| Interest expense | 1.23B CNY | 1.55B CNY | 1.32B CNY | 963.81M CNY | 822.53M CNY |
| Depreciation and amortization | 3.63B CNY | 3B CNY | 2.97B CNY | 2.34B CNY | 1.83B CNY |
| Operating income | 2.54B CNY | 4.25B CNY | 3.31B CNY | 8.3B CNY | 6.31B CNY |
| Net income | 3.28B CNY | 2.77B CNY | 2.39B CNY | 3.73B CNY | 4.73B CNY |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Cash distributions grouped by calendar year; partial years are marked.
HK$0.35
2025 complete year-32.7% since 2021
2026 partial: HK$0.45
HK$0.52
2,021
HK$0.66
2,022
HK$0.46
2,023
HK$0.30
2,024
HK$0.35
2,025
HK$0.45
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jul 16, 2026 | HK$0.45Annual | Jul 17, 2026 | Aug 14, 2026 |
Dividend | Jul 24, 2025 | HK$0.35Annual | Jul 25, 2025 | Aug 22, 2025 |
Dividend | Jul 26, 2024 | HK$0.30Annual | Jul 29, 2024 | Aug 23, 2024 |
Dividend | Jul 31, 2023 | HK$0.46Annual | Aug 1, 2023 | Aug 24, 2023 |
Dividend | Jun 8, 2022 | HK$0.66Annual | Jun 9, 2022 | Jul 4, 2022 |
Dividend | Jul 7, 2021 | HK$0.52Annual | Jul 8, 2021 | Aug 3, 2021 |
Ex-dividend Jul 16, 2026
HK$0.45
Annual
Record Jul 17, 2026 · Payment Aug 14, 2026
Ex-dividend Jul 24, 2025
HK$0.35
Annual
Record Jul 25, 2025 · Payment Aug 22, 2025
Ex-dividend Jul 26, 2024
HK$0.30
Annual
Record Jul 29, 2024 · Payment Aug 23, 2024
Ex-dividend Jul 31, 2023
HK$0.46
Annual
Record Aug 1, 2023 · Payment Aug 24, 2023
Ex-dividend Jun 8, 2022
HK$0.66
Annual
Record Jun 9, 2022 · Payment Jul 4, 2022
Ex-dividend Jul 7, 2021
HK$0.52
Annual
Record Jul 8, 2021 · Payment Aug 3, 2021
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard FTSE Emerging Markets ETFVWO14.52M0.01%162.3B USD0.06%$60.35+0.69%
Vanguard Total International Stock ETFVXUS13.86M0.00%646.2B USD0.05%$87.14+1.00%
Vanguard FTSE All-World ex-US ETFVEU3.21M0.00%95.9B USD0.04%$85.18+1.04%
Vanguard International High Dividend Yield ETFVYMI1.29M0.01%21.9B USD0.07%$105.6+0.83%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM1.1M0.01%9.62B USD0.39%$40.53+1.12%
Schwab Emerging Markets Equity ETFSCHE1.1M0.01%13.02B USD0.06%$37.02+0.73%
Vanguard Total World Stock ETFVT774.27K0.00%97.9B USD0.06%$159.94+0.89%
WisdomTree China ex-State-Owned Enterprises FundCXSE489.54K0.10%475.2M USD0.32%$36.2287+0.47%Vanguard FTSE Emerging Markets ETFVWOVanguard Total International Stock ETFVXUSVanguard FTSE All-World ex-US ETFVEUVanguard International High Dividend Yield ETFVYMIDimensional - Emerging Markets Core Equity 2 ETFDFEMSchwab Emerging Markets Equity ETFSCHEVanguard Total World Stock ETFVTWisdomTree China ex-State-Owned Enterprises FundCXSEAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
